10207- IMT-4 REAL-WORLD DATA AND IMMUNOHISTOLOGICAL STUDY OF AUTOLOGOUS FORMALIN-FIXED TUMOR VACCINE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Shunichi Koriyama, Masayuki Nitta, Shunsuke Tsuzuki, Tatsuya Kobayashi, Wendong Lyu, Takashi Komori, Kenta Masui, Takakazu Kawamata, Yoshihiro Muragaki · 2024
Read 10207- IMT-4 REAL-WORLD DATA AND IMMUNOHISTOLOGICAL STUDY OF AUTOLOGOUS FORMALIN-FIXED TUMOR VACCINE FOR NEWLY DIAGNOSED GLIOBLASTOMA by Shunichi Koriyama, Masayuki Nitta, Shunsuke Tsuzuki, Tatsuya Kobayashi, Wendong Lyu, Takashi Komori, Kenta Masui, Takakazu Kawamata, Yoshihiro Muragaki (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11605562.txt.
Description
Shunichi Koriyama and co-authors report real-world results for a personalized tumor vaccine in newly diagnosed glioblastoma, in a 2024 conference paper. The vaccine, made from the patient's own formalin-fixed tumor, was added to standard chemotherapy and radiation at their institution. Records covered 402 patients treated from 2005 to 2021, 158 vaccinated and 244 not.
The vaccine group lived far longer: median survival 31.3 months against 19.4, and time without progression 15.0 against 7.8 months. Gains persisted in elderly patients and in early relapses, and were largest after full tumor removal. A marker analysis hinted that tumors without PD-L1 expression responded best. The authors back multidisciplinary care including the vaccine.
Catalog record
| CREATOR | Shunichi Koriyama, Masayuki Nitta, Shunsuke Tsuzuki, Tatsuya Kobayashi, Wendong Lyu, Takashi Komori, Kenta Masui, Takakazu Kawamata, Yoshihiro Muragaki |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |